Royce & Associates LP Invests $8.34 Million in Bioventus Inc. (NYSE:BVS)

Royce & Associates LP bought a new position in shares of Bioventus Inc. (NYSE:BVS) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 697,696 shares of the company’s stock, valued at approximately $8,337,000. Royce & Associates LP owned 0.86% of Bioventus at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Bioventus in the 1st quarter valued at $66,000. Acadian Asset Management LLC acquired a new position in Bioventus during the 1st quarter worth about $28,000. Hillsdale Investment Management Inc. lifted its position in Bioventus by 26.1% during the 1st quarter. Hillsdale Investment Management Inc. now owns 34,742 shares of the company’s stock worth $181,000 after buying an additional 7,200 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Bioventus during the 1st quarter valued at about $40,000. Finally, Kennedy Capital Management LLC lifted its position in Bioventus by 66.8% during the 1st quarter. Kennedy Capital Management LLC now owns 120,134 shares of the company’s stock valued at $625,000 after purchasing an additional 48,111 shares during the period. Institutional investors own 62.94% of the company’s stock.

Analyst Ratings Changes

BVS has been the subject of a number of recent analyst reports. Canaccord Genuity Group upped their price target on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Craig Hallum raised their price target on shares of Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, September 27th.

Bioventus Trading Up 1.0 %

Shares of Bioventus stock opened at $11.24 on Monday. The stock has a market cap of $912.13 million, a PE ratio of -18.43 and a beta of 0.88. The firm has a 50-day moving average of $11.97 and a 200-day moving average of $8.73. Bioventus Inc. has a 52-week low of $3.64 and a 52-week high of $14.38. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Bioventus (NYSE:BVS) last issued its earnings results on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting the consensus estimate of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The firm had revenue of $138.96 million during the quarter, compared to the consensus estimate of $132.57 million. During the same quarter in the previous year, the firm earned $0.05 earnings per share. As a group, sell-side analysts forecast that Bioventus Inc. will post 0.41 EPS for the current year.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.